Phase 3
Completed N=133
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
Source: ClinicalTrials.gov NCT02504541 ↗Enrolled (actual)
133
Serious AEs
3.0%
Results posted
Mar 2018
Primary outcomePrimary: Incidence of Adverse Events as a Measure of Safety of QuickShot™ Testosterone (QST) Administered Subcutaneously (SC) Once Each Week to Adult Males With Hypogonadism — 87; 34; 4; 8 Participants
◆ Published Evidence
Established
32citations · ~5 / year
Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Summary
Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.
Linked Publications
-
Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Adverse Events as a Measure of Safety of QuickShot™ Testosterone (QST) Administered Subcutaneously (SC) Once Each Week to Adult Males With Hypogonadism |
87; 34; 4; 8; 4 | — |
Eligibility Criteria
Inclusion Criteria
- Adult men ≥18 and ≤75 years of age with a documented history of hypogonadism
- Total testosterone levels 50 mL of blood or plasma within 3 months of screening.
- Donation of plasma or blood during study
Data sourced from ClinicalTrials.gov (NCT02504541) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.